The Market Reports

Synopsis
The global market for Generic Drugs was estimated to be worth US$ 267220 million in 2024 and is forecast to a readjusted size of US$ 401690 million by 2031 with a CAGR of 5.3% during the forecast period 2025-2031.
A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. The term may also refer to any drug marketed under its chemical name without advertising, or to the chemical makeup of a drug rather than the brand name under which the drug is sold.
The generic drugs market is driven by the rising demand for cost-effective medications, especially as healthcare systems worldwide face increasing financial pressures. The expiration of patents on numerous blockbuster drugs opens opportunities for generic manufacturers to enter the market with more affordable alternatives. Additionally, supportive government policies, regulatory incentives, and growing acceptance of generics by healthcare providers and patients contribute to the market’s rapid expansion.
A key challenge in the generic drugs market is the intense price competition, which can squeeze profit margins and discourage innovation. Regulatory hurdles and delays in approval processes can also limit timely market entry. Furthermore, concerns about the quality and consistency of some generics—particularly in developing markets—may affect consumer trust and hinder adoption despite cost advantages.
This report aims to provide a comprehensive presentation of the global market for Generic Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Generic Drugs by region & country, by Type, and by Application.
The Generic Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Generic Drugs.
Market Segmentation
By Company
Teva
Sandoz
Viatris
Sun Pharmaceutical
Aspen
Fresenius Kabi
Pfizer (Hospira)
Sanofi
Aurobindo
Lupin
Dr. Reddy's
Apotex
Cipla
ENDO (Par Pharmaceutical)
Stada Arzneimittel
Krka Group
Nichi-Iko Pharmaceutical
Valeant
Zydus Cadila
Hikma
Pharmaniaga Berhad
Hovid Berhad
Duopharma Biotech
Kotra Pharma
HOE Pharmaceutical
Y.S.P. Industries
Segment by Type
Prescription
Non-Prescription Drugs
Segment by Application
CNS
Cardiovascular
Genitourinary/Hormonal Drugs
Respiratory
Rheumatology
Diabetes
Oncology
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Generic Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Generic Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Generic Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Index